Ind-Swift Laboratories share news, announcements and annual reports
NSE: INDSWFTLABBSE: 532305Pharmaceuticals & BiotechnologySmall Cap
Ind-Swift Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1997 on NSE, Mar 2000 on BSE
Last close ₹378.95up ₹10.15 (2.75%)BSE ₹379.45
Share price at the NSE close on 28 Oct 2026. Previous close ₹368.80.
28 Oct: open ₹376.20, high ₹382.00, low ₹363.00
52-week range of traded prices to 28 Oct 2026
₹87.15Low, 31 Dec 2025₹424.75High, 30 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,295 Cr1,404th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.49
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 48.06
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.38
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 5.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,89,73643.1% delivered
Ind-Swift Laboratories orders, deals and press releases
55 filed, newest first. Page 2 of 2.
Feb 2011
Jan 2011
31 Jan · Business
Board of Directors of the Company have, in its meeting held on January 29, 2011, allotted 10,00,000 equity shares of Rs.10/- each at a premium of Rs.40/- per shares to Promoters Group upon the conversion of 10,00,000 Zero Coupon Optionally Convertible Warrants (2009 Series).
Nov 2010
15 Nov · Business
Board of Directors of the Company at its meeting held on November 13, 2010, approved the Allotment of 1,85,660 Shares to employees under Employee Stock Option Plan (ESOP).
Oct 2010
21 Oct · Business
Board of Directors of the Company in its meeting held on October 21, 2010, allotted 80,00,000 Zero Coupon Optionally Convertible Warrants (Series 2010) to Promoters Group Companies and other Bodies Corporate at a price of Rs. 82.50/- per warrant.
Feb 2007
8 Feb · Business
Ind-Swift Laboratories Ltd. has informed the Exchange regarding a press release, titled "Ind-Swift Laboratories Limited undergoes successful USFDA audit". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.